Equities Analysts Set Expectations for C4 Therapeutics FY2029 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Stock analysts at Brookline Capital Management issued their FY2029 EPS estimates for C4 Therapeutics in a research report issued to clients and investors on Monday, January 6th. Brookline Capital Management analyst L. Cann anticipates that the company will earn $28.08 per share for the year. The consensus estimate for C4 Therapeutics' current full-year earnings is ($1.52) per share.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.05. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The business had revenue of $15.36 million during the quarter, compared to the consensus estimate of $5.95 million.

A number of other equities analysts have also recently weighed in on the stock. Stephens assumed coverage on shares of C4 Therapeutics in a research note on Monday, November 18th. They set an "equal weight" rating and a $4.00 price target on the stock. Wells Fargo & Company raised C4 Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $8.00 to $12.00 in a research note on Thursday, December 19th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.67.

C4 Therapeutics Stock Performance

NASDAQ:CCCC traded down $0.02 during trading hours on Wednesday, hitting $3.84. The company's stock had a trading volume of 1,397,519 shares, compared to its average volume of 1,566,639. C4 Therapeutics has a 52-week low of $3.43 and a 52-week high of $11.88. The business's 50-day moving average is $4.44 and its two-hundred day moving average is $5.38. The company has a market capitalization of $271.06 million, a PE ratio of -2.26 and a beta of 2.96.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC purchased a new position in C4 Therapeutics during the second quarter worth $45,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of C4 Therapeutics during the second quarter valued at $51,000. Point72 DIFC Ltd purchased a new stake in C4 Therapeutics during the 3rd quarter worth about $51,000. Cynosure Group LLC acquired a new position in C4 Therapeutics in the 3rd quarter valued at about $57,000. Finally, Aigen Investment Management LP purchased a new position in C4 Therapeutics in the 3rd quarter valued at about $82,000. 78.81% of the stock is currently owned by institutional investors and hedge funds.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.